Literature DB >> 11575870

Inhalational and topical steroids, and oral candidosis: a mini review.

A N Ellepola1, L P Samaranayake.   

Abstract

Candidosis is by far the commonest oral fungal infection in man and could manifest as an adverse effect of drug therapy such as inhaled or topically applied corticosteroids. Due to the anti-inflammatory and immunosuppressive effect steroids are used in the management of bronchial asthma and oral mucosal diseases. In this mini review we discuss the clinical and laboratory findings on the relationship between steroid inhalers, other topical steroids and oral candidosis, possible mechanisms of pathogenicity following such therapy as well as the precautions that could be taken to minimize this adverse side effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575870

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  17 in total

1.  The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers.

Authors:  Hugh D C Smyth; Vance P Beck; Dennis Williams; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2004-02-10       Impact factor: 3.246

Review 2.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

3.  Oral viscous budesonide as a first-line approach to esophageal stenosis in epidermolysis bullosa: an open-label trial in six children.

Authors:  Andrea Zanini; Sophie Guez; Simona Salera; Giorgio Farris; Anna Morandi; Valerio Gentilino; Ernesto Leva; Francesca Manzoni; Maria Angela Pavesi; Susanna Esposito; Francesco Macchini
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

4.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

5.  Oral Candida carriage and species prevalence amongst habitual gutka-chewers and non-chewers.

Authors:  Fawad Javed; Howard C Tenenbaum; Getulio Nogueira-Filho; Nasser Nooh; Tara B Taiyeb Ali; Lakshman P Samaranayake; Khalid Al-Hezaimi
Journal:  Int Wound J       Date:  2012-08-10       Impact factor: 3.315

6.  Prevalence of oral Candida carriage and Candida species among cigarette and maras powder users.

Authors:  Hamit Sirri Keten; Derya Keten; Huseyin Ucer; Fatis Yildirim; Hakan Hakkoymaz; Oguz Isik
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  Candida albicans Mds3p, a conserved regulator of pH responses and virulence identified through insertional mutagenesis.

Authors:  Dana A Davis; Vincent M Bruno; Lucio Loza; Scott G Filler; Aaron P Mitchell
Journal:  Genetics       Date:  2002-12       Impact factor: 4.562

8.  Ciclesonide for the treatment of asthma.

Authors:  Ronald Dahl
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

9.  Impact of brief exposure to antifungal agents on the post-antifungal effect and hemolysin activity of oral Candida albicans.

Authors:  Arjuna Nishantha Ellepola; Rana Khajah; Sumedha Jayatilake; Lakshman Samaranayake; Prem Sharma; Zia Khan
Journal:  J Appl Oral Sci       Date:  2015 Jul-Aug       Impact factor: 2.698

10.  Changes in the cell surface hydrophobicity of oral Candida albicans from smokers, diabetics, asthmatics, and healthy individuals following limited exposure to chlorhexidine gluconate.

Authors:  Arjuna N B Ellepola; Bobby K Joseph; Z U Khan
Journal:  Med Princ Pract       Date:  2012-12-18       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.